Latest News in the pharma Industry

Policy & Regulation

Antibiotic Approved for Treating Infant Abdominal Infections

Antibiotic Approved for Treating Infant Abdominal Infections

29 May 2015

Read more 
Salix Announces FDA Approval of Xifaxan 550 mg for the Treatment of IBS-D

Salix Announces FDA Approval of Xifaxan 550 mg for the Treatment of IBS-D

28 May 2015

Read more 
Actavis Receives FDA Approval for Viberzi (Eluxadoline) for the Treatment of IBS-D in Adults

Actavis Receives FDA Approval for Viberzi (Eluxadoline) for the Treatment of IBS-D in Adults

28 May 2015

Read more 
GVK Biosciences: EMA Confirms Recommendation to Suspend Medicines Over Flawed Studies

GVK Biosciences: EMA Confirms Recommendation to Suspend Medicines Over Flawed Studies

27 May 2015

Read more 
Amgen Receives Positive CHMP Opinion for Use of Repatha (Evolocumab) for the Treatment of High Cholesterol

Amgen Receives Positive CHMP Opinion for Use of Repatha (Evolocumab) for the Treatment of High Cholesterol

26 May 2015

Read more 
FDA Approves Boehringer Ingelheim’s Stiolto Respimat as Once-Daily Maintenance Treatment for COPD

FDA Approves Boehringer Ingelheim’s Stiolto Respimat as Once-Daily Maintenance Treatment for COPD

26 May 2015

Read more 
Merck Receives Positive CHMP Opinion for Keytruda for the Treatment of Advanced Melanoma

Merck Receives Positive CHMP Opinion for Keytruda for the Treatment of Advanced Melanoma

25 May 2015

Read more 
BMS Receives Positive CHMP Opinion in the EU for Nivolumab (Opdivo, Nivolumab BMS) for the Treatment of Advanced Squamous NSCLC in Previously-Treated Patients

BMS Receives Positive CHMP Opinion in the EU for Nivolumab (Opdivo, Nivolumab BMS) for the Treatment of Advanced Squamous NSCLC in Previously-Treated Patients

22 May 2015

Read more 
BMS Receives Amended FDA Breakthrough Therapy Designation for Investigational Daclatasvir-Based Hepatitis C Regimen

BMS Receives Amended FDA Breakthrough Therapy Designation for Investigational Daclatasvir-Based Hepatitis C Regimen

21 May 2015

Read more 
Baxter Receives FDA Approval for 0.9% Sodium Chloride Injection, USP from Sabinanigo, Spain, Facility for the US Market

Baxter Receives FDA Approval for 0.9% Sodium Chloride Injection, USP from Sabinanigo, Spain, Facility for the US Market

20 May 2015

Read more 
FDA Performs GMP and Pre-Approval Inspections of Impax's Hayward Facility

FDA Performs GMP and Pre-Approval Inspections of Impax's Hayward Facility

12 May 2015

Read more 
Novartis Lung Cancer Drug Zykadia Gains EU Approval, Providing New Therapy for Certain Patients with ALK+ NSCLC

Novartis Lung Cancer Drug Zykadia Gains EU Approval, Providing New Therapy for Certain Patients with ALK+ NSCLC

8 May 2015

Read more